Mylan, Teva Launch Generic Diovan Antihypertensive Agent

Mylan and Teva have separately announced the US launches of their respective valsartan tablets, the generic version of Novartis' antihypertensive agent, Diovan.

Mylan and Teva have separately announced the US launches of their respective valsartan tablets, the generic version of Novartis’ antihypertensive agent, Diovan.

The companies’ announcements follow the FDA’s final approval of Abbreviated New Drug Applications from both Mylan and Teva for the products, which are indicated to lower blood pressure in patients with hypertension.

Both generic versions of valsartan will be available in 40 mg, 80 mg, 160 mg, and 320 mg tablets, which had approximately $2 billion worth of sales in the United States for the 12-month period ending on September 30, 2014, according to IMS Health. Novartis’ brand name Diovan had annual sales of approximately $1.8 billion in the United States, according to IMS data through October 2014.